Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab

Item Type:Article
Title:Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab
Creators Name:Trappe, R. and Riess, H. and Babel, N. and Hummel, M. and Lehmkuhl, H. and Jonas, S. and Anagnostopoulos, I. and Papp-Vary, M. and Reinke, P. and Hetzer, R. and Doerken, B. and Oertel, S.
Abstract:Background: Single-agent rituximab has demonstrated encouraging efficacy and tolerability in posttransplant lymphoproliferative disorders (PTLDs) failing to respond to immunosuppression reduction (IR). This retrospective analysis was undertaken to determine the efficacy and safety of salvage therapy in recipients of solid organ transplants with progression of PTLD after rituximab first-line therapy. Methods: Eleven patients who had received IR and single-agent rituximab were analyzed. Of these, 10 had received CHOP salvage chemotherapy. One patient with limited disease received tumor irradiation and further IR. Most patients (73%) had late PTLD (median onset of disease 145 months posttransplant), and most (83%) had monomorphic histology; 36% had EBV-association. RESULTS: IR and irradiation therapy re-induced complete remission (CR) and allowed long-term disease control in a patient with polymorphic PTLD relapse. CHOP therapy achieved CR in five (50%) and partial remission (PR) in two (20%) patients. Four of five (80%) patients achieving CR remained in CR at a median follow-up of 44.2 months. Of the patients achieving PR, one is currently alive, and the second died from transplant rejection after converting to CR after consolidative chemotherapy. Patients with stable disease (two) and progressive disease (one) have died from PTLD. There was one possible CHOP-associated death (acute cardiac event) and two patients had to be switched to less-toxic monotherapies. Median overall survival was 46.5 months (95% confidence interval: 23.6-49.1 months). Conclusions: CHOP salvage therapy achieved a favorable overall response rate of 70% in this setting, indicating that PTLD generally remains chemotherapy-sensitive after progression following first-line rituximab.
Keywords:Posttransplant lymphoproliferative disorders (PTLD), Rituximab, CHOP, Salvage chemotherapy
Source:Transplantation
ISSN:0041-1337
Publisher:Lippincott Williams & Wilkins (U.S.A.)
Volume:83
Number:7
Page Range:912-918
Date:15 April 2007
Official Publication:https://doi.org/10.1097/01.tp.0000258647.50947.78
PubMed:View item in PubMed

Repository Staff Only: item control page

Open Access
MDC Library